<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230408057849N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-04</date_registration>
      <primary_sponsor>Islamic Azad University of Marvdasht</primary_sponsor>
      <public_title>Investigating the effect of fluoxetine and online compassion-focused therapy in the treatment of post-chronic patients with post-traumatic stress disorder</public_title>
      <acronym></acronym>
      <scientific_title>The Comparison of the Effectiveness of Pharmacotherapy and online Compassion-Based Therapy in Reducing the Severity of Post Traumatic Symptoms, Increasing Post-Traumatic Growth, Improving Quality of life, and Studying Changes in Hippocampal and Amygdala Volume in Improved Patients with Coronavirus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69474</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic.</study_design>
      <phase>1-2</phase>
      <hc_freetext>Post Traumatic Stress Disorder.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: Pharmacotherapy: Prozac brand name، fluoxetine drug from the serotonin reuptake inhibitors (SSRIs) category at a dose of 20 mg, 2 times a day, morning and evening, in a period of 6 to 8 weeks, Exir pharmaceutical factory. Intervention 2: The  intervention group: Compassion-focused therapy, online, in eight ninety-minute sessions, once a week and in a group setting. description of meetings; The first session: getting to know the group members with each other, explaining the group rules, explaining the symptoms of post-traumatic stress, talking about their problems, explaining how the mind works and how and why it malfunctions. The second session: explanation and description of compassion: what compassion is and how to overcome problems through it. The third session: thinking about compassion towards others, paying attention and focusing on compassion, thinking about compassionate compassion, compassionate behavior, portraying compassion The fourth session: increasing warmth and energy, mindfulness, acceptance, wisdom and strength, warmth and non-judgment. Sixth session: practice the color of compassion, sound and image of compassion, and letter writing based on compassion .Seventh session: writing letters of compassion, practicing anger and compassion, practicing fear of compassion, preparing for the end of the group. Eighth session: reviewing, summarizing, ending the group's work, and doing the post-test. Intervention 3: Control group: They did not receive any intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts one year after the results are published

To whom:
The data of this study will be available only to researchers working in academic and scientific institutions

Conditions:
The data of this study will be used in other similar researches for resources

Where to obtain:
Future researchers should contact the responsible author via email to use the data of this study.
fatemehmodaresifard@gmail.com

How to obtain:
After sending the request email, the responsible author will send the data within a period of 7 days

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Modaresifard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 7, Vafaie Blvd. 21Ave., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7147885359</zip>
        <telephone>+98 71 3734 5881</telephone>
        <email>fatemehmodaresifard@gmail.com</email>
        <affiliation>American Psychological Association</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mohsen Zamir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Nawab St., Shahid Salmani Alley. Qazvin University of Medical Sciences</address>
        <city>Ghazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3419759811</zip>
        <telephone>009822833336001-5</telephone>
        <email>omidzamir@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1- Being a resident of Shiraz city 2- having a positive PCR in Delta variant Corona virus 3- having a history of hospitalization and discharge.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Older participant
Not living in Shiraz city
Not having a history of hospitalization in the corona ward</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F43.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Post-traumatic stress disorder (PTSD)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Lifestyle</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: Pharmacotherapy: Prozac brand name، fluoxetine drug from the serotonin reuptake inhibitors (SSRIs) category at a dose of 20 mg, 2 times a day, morning and evening, in a period of 6 to 8 weeks, Exir pharmaceutical factory</i_keyword>
      <i_keyword>The  intervention group: Compassion-focused therapy, online, in eight ninety-minute sessions, once a week and in a group setting. description of meetings; The first session: getting to know the group members with each other, explaining the group rules, explaining the symptoms of post-traumatic stress, talking about their problems, explaining how the mind works and how and why it malfunctions. The second session: explanation and description of compassion: what compassion is and how to overcome problems through it. The third session: thinking about compassion towards others, paying attention and focusing on compassion, thinking about compassionate compassion, compassionate behavior, portraying compassion The fourth session: increasing warmth and energy, mindfulness, acceptance, wisdom and strength, warmth and non-judgment. Sixth session: practice the color of compassion, sound and image of compassion, and letter writing based on compassion .Seventh session: writing letters of compassion, practicing anger and compassion, practicing fear of compassion, preparing for the end of the group. Eighth session: reviewing, summarizing, ending the group's work, and doing the post-test</i_keyword>
      <i_keyword>Control group: They did not receive any intervention</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The percentage of people whose questionnaire  score was reported to be low. Timepoint: Measuring the severity of post-traumatic stress symptoms, one week before the start of the intervention (pre-test) and 2 weeks after the intervention (post-test) and for the follow-up stage 3 months after the intervention. Method of measurement: Post-traumatic growth and development questionnaire, post-traumatic stress disorder questionnaire (PCL-5), World Health Organization quality of life questionnaire - short form, brain imaging to measure the Hippocampus and Amygdala.</prim_outcome>
      <prim_outcome>The percentage of people whose questionnaire scores are high. Timepoint: Measurement of growth and development after the accident, one week before the start of the intervention (pre-test) and 2 weeks after the intervention (post-test) and for the follow-up stage 3 months after the intervention. Method of measurement: Post-traumatic growth and development questionnaire.</prim_outcome>
      <prim_outcome>The percentage of people whose  questionnaire scores are reported to be high. Timepoint: Measuring the quality of life, one week before the start of the intervention (pre-test) and 2 weeks after the intervention (post-test) and for the follow-up stage 3 months after the intervention. Method of measurement: World Health Organization quality of life questionnaire - short form.</prim_outcome>
      <prim_outcome>Changes in the size of the Hippocampus and Amygdala. Timepoint: At the beginning of the study (before the interventions) and one year after the interventions. Method of measurement: Brain imaging to measure the hippocampus and amygdala.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The financial sponsor of this thesis is the PhD student, Mrs. Fateme Modaresi Fard</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-20</approval_date>
        <contact_name>سامانه ملی اخلاق در پژوهش های زیست پزشکی</contact_name>
        <contact_address>Floor.13, Block A, Ministry of Health &amp; Medical Education Headquarters, Between Zarafashan &amp; South Falamak, Qods Town, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
